Capital World Investors Allogene Therapeutics, Inc. Transaction History
Capital World Investors
- $597 Billion
- Q2 2024
A detailed history of Capital World Investors transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Capital World Investors holds 6,896,552 shares of ALLO stock, worth $20.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,896,552Holding current value
$20.4 Million% of portfolio
0.0%Shares
13 transactions
Others Institutions Holding ALLO
# of Institutions
176Shares Held
132MCall Options Held
94.3KPut Options Held
112K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$55.4 Million1.08% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$48.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$24.3 Million0.0% of portfolio
-
State Street Corp Boston, MA7.67MShares$22.7 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.79MShares$17.1 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $426M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...